United States - English - NLM (National Library of Medicine)

amryt pharmaceuticals dac - metreleptin (unii: tl60c27rlh) (metreleptin - unii:tl60c27rlh) - metreleptin 11.3 mg in 2.2 ml - myalept (metreleptin) for injection is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. limitations of use - the safety and effectiveness of myalept for the treatment of complications of partial lipodystrophy have not been established. - the safety and effectiveness of myalept for the treatment of liver disease, including nonalcoholic steatohepatitis (nash), have not been established. - myalept is not indicated for use in patients with hiv-related lipodystrophy. - myalept is not indicated for use in patients with metabolic disease, including diabetes mellitus and hypertriglyceridemia, without concurrent evidence of congenital or acquired generalized lipodystrophy. myalept is contraindicated in patients with general obesity not associated with congenital leptin deficiency. myalept has not been shown to be effective in treating general obesity, and the development of anti-metreleptin antibodi

United States - English - NLM (National Library of Medicine)

catalent pharma solution, llc - metreleptin (unii: tl60c27rlh) (metreleptin - unii:tl60c27rlh) - metreleptin 11.3 mg in 2.2 ml

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

shionogi & co., ltd. - metreleptin (genetical recombination) - white and clumped injectable preparation

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

arpimed llc - clozapine - tablets - 100mg

European Union - English - EMA (European Medicines Agency)

amryt pharmaceuticals dac - metreleptin - lipodystrophy, familial partial - other alimentary tract and metabolism products, - myalepta is indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (ld) patients:with confirmed congenital generalised ld (berardinelli-seip syndrome) or acquired generalised ld (lawrence syndrome) in adults and children 2 years of age and abovewith confirmed familial partial ld or acquired partial ld (barraquer-simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control.

Israel - English - Ministry of Health

novartis israel ltd - oxcarbazepine - film coated tablets - oxcarbazepine 300 mg - oxcarbazepine - oxcarbazepine - treatment of primary generalised tonic-clonic seizures and partial seizures with or without secondary generalization.

Israel - English - Ministry of Health

novartis israel ltd - oxcarbazepine - film coated tablets - oxcarbazepine 600 mg - oxcarbazepine - oxcarbazepine - treatment of primary generalized tonic-clonic seizures and partial seizures with or without secondary generalization.

Israel - English - Ministry of Health

novartis israel ltd - carbamazepine - tablets - carbamazepine 200 mg - carbamazepine - carbamazepine - epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in manic depressive illness.

Israel - English - Ministry of Health

novartis israel ltd - carbamazepine - tablets slow release - carbamazepine 400 mg - carbamazepine - carbamazepine - epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in mania depressive illness.

Israel - English - Ministry of Health

novartis israel ltd - carbamazepine - tablets slow release - carbamazepine 200 mg - carbamazepine - carbamazepine - epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in manic-depressive illness